NTI drugs and Full Replicate [Design Issues]

posted by Pharma_88 – India, 2020-03-10 06:39 (357 d 18:11 ago) – Posting: # 21232
Views: 4,006

Dear All,


For NTI drugs, USFDA suggested to perform full replicate design despite of having low to moderate ISCV. My question is that is there any specific guidance is available from FDA behind this rationale? Further, can we perform crossover studies for NTI by taking extra safety measurement in to the study? Further, what is the BE limit for such drugs? 2003 guidelines having information on NTI however draft 2014 doesn't have any info for NTI.

For Example, FDA suggested to perform BE for Sodium valporic acid as full replicate despite of having low ISCV. However, available PAR reports having crossover design.


Complete thread:

 Admin contact
21,359 posts in 4,460 threads, 1,492 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Wednesday 00:51 CET (Europe/Vienna)

The art and science of asking questions
is the source of all knowledge.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz